Home > Insider Trading > Filing (0001179110-13-011151)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1434868	Esperion Therapeutics Inc.	ESPR	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1238401	G Louis Lange	C/O Esperion Therapeutics, Inc. 46701 Commerce Center Drive Plymouth MI 48170		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-07-01	186,989	$0.00	186,989	No	4	C	Indirect	By Asset Management Company Venture Fund, L.P.
Common Stock	Acquisiton	2013-07-01	14,314	$0.00	14,314	No	4	C	Direct
Common Stock	Acquisiton	2013-07-01	3,500	$14.00	17,814	No	4	P	Direct
Common Stock	Acquisiton	2013-07-01	10,714	$14.00	197,703	No	4	P	Indirect	By Asset Management Company Venture Fund, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Asset Management Company Venture Fund, L.P.
No	4	C	Direct
No	4	P	Direct
No	4	P	Indirect	By Asset Management Company Venture Fund, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2013-07-01	186,989	$0.00	186,989	$0.00
Common Stock	Series A Preferred Stock	Disposition	2013-07-01	14,314	$0.00	14,314	$0.00
Series A Preferred Stock	Warrant to Purchase Preferred Stock	Disposition	2013-07-01	51,230	$0.00	51,230	$1.00
Common Stock	Warrant to Purchase Common Stock	Acquisiton	2013-07-01	7,333	$0.00	7,333	$6.99

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Indirect
0		No	4	C	Direct
0	2018-02-12	No	4	J	Indirect
7,333	2018-02-12	No	4	J	Indirect

Footnotes

The Series A Preferred Stock was automatically converted into Common Stock on a 6.986-for-1 basis upon the closing of the Issuer's initial public offering without payment of further consideration and had no expiration date.
The reportable securities are owned directly by Asset Management Company Venture Fund, L.P. ("AMCVF"). The general partner of AMCVF is Asset Management Ventures (GP) LLC ("AMV GP"). Dr. Lange is a managing member of AMV GP, and he disclaims beneficial ownership of the shares held by AMCVF, except to the extent of his pecuniary interest therein.
Upon the closing of the Issuer's initial public offering, this warrant to purchase shares of Series A Preferred Stock automatically converted on a 6.986-for-1 basis into a warrant to purchase shares of Common Stock, and the exercise price automatically adjusted accordingly. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrant and the change in exercise price.
The warrant is immediately exercisable.